Scinai Immunotherapeutics Files October 6-K Report
Ticker: SCNI · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, regulatory-filing, company-update
TL;DR
Scinai Immunotherapeutics filed its October 6-K, confirming its foreign private issuer status and principal office in Israel.
AI Summary
Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on October 15, 2024. This report is for the month of October 2024 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive office is located in Jerusalem, Israel.
Why It Matters
This filing provides an update on Scinai Immunotherapeutics' regulatory reporting status as a foreign private issuer. Investors should monitor these filings for any material changes or disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain specific financial or operational disclosures that would immediately indicate high risk.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- October 15, 2024 (date) — Filing date
- Jerusalem, Israel (location) — Principal executive office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
What was Scinai Immunotherapeutics Ltd.'s former name?
Scinai Immunotherapeutics Ltd.'s former name was BiondVax Pharmaceuticals Ltd.
When was the name change from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd.?
The date of the name change was June 24, 2014.
Where is Scinai Immunotherapeutics Ltd.'s principal executive office located?
The company's principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
What is the SEC file number for Scinai Immunotherapeutics Ltd.?
The SEC file number for Scinai Immunotherapeutics Ltd. is 001-37353.
Filing Stats: 374 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-10-15 15:33:59
Filing Documents
- ea0217508-6k_scinai.htm (6-K) — 32KB
- ea021750801ex99-1_scinai.htm (EX-99.1) — 214KB
- ea021750801ex99-2_scinai.htm (EX-99.2) — 10KB
- tproxy_001.jpg (GRAPHIC) — 687KB
- tproxy_002.jpg (GRAPHIC) — 822KB
- 0001213900-24-087739.txt ( ) — 2336KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Scinai Immunotherapeutics Ltd. Date: October 15, 2024   By:   /s/ Amir Reichman         Amir Reichman         Chief Executive Officer 2